Monopar Therapeutics (MNPR) Share-based Compensation Growth (1y) (2018 - 2025)
Monopar Therapeutics (MNPR) Share-based Compensation Growth (1y) (2018 - 2025) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 118.32% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -40.86% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Monopar Therapeutics | 707.36 Mn | 645.53 Mn | - | -176.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -176.24% |
| Sep 30, 2025 | 5,799.99% |
| Jun 30, 2025 | 4,759.62% |
| Mar 31, 2025 | 2,881.80% |
| Dec 31, 2024 | 417.14% |
| Sep 30, 2024 | -35.52% |
| Jun 30, 2024 | -40.65% |
| Mar 31, 2024 | 47.20% |
| Dec 31, 2023 | -461.87% |
| Sep 30, 2023 | 10.06% |
| Jun 30, 2023 | 99.92% |
| Mar 31, 2023 | -55.33% |
| Dec 31, 2022 | 12.35% |
| Sep 30, 2022 | -47.61% |
| Jun 30, 2022 | -57.33% |
| Mar 31, 2022 | 35.73% |
| Dec 31, 2021 | -15.17% |
| Sep 30, 2021 | 38.19% |
| Jun 30, 2021 | -2.66% |
| Mar 31, 2021 | 8.78% |